Retatrutide
Phase 3aka LY3437943
Triple agonist (GLP-1, GIP, glucagon) in phase 3 for obesity. The one everyone's watching.
Mechanism
One molecule hitting three metabolic receptors at once: GLP-1, GIP, and glucagon. The glucagon arm is the interesting part, it bumps energy expenditure on top of the appetite suppression you already get from a GLP-1. On paper it should out-cut tirzepatide, and the phase 2 numbers backed that up.
Regulatory & Safety Status
Still investigational. Lilly's compound, no regulator has signed off, so everything you read is trial data. Anything sold to you right now is grey market.
Research
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice
GLP-1 and dual GIP/GLP-1 receptor agonists' psychopharmacology and putative neuropsychiatric associated effects: a Bradford Hill-informed, systematic, evaluation
Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application
Retatrutide phase 2 obesity trial
Phase 2 RCT reporting dose-dependent weight reduction over 48 weeks.
Latest retatrutide research